Oct 31, 2025 09:54AM
Feb 28, 2024 07:00AM
Nov 3, 2023 07:00AM
Oct 16, 2023 08:06AM
Oct 16, 2023 08:00AM
Aug 28, 2023 07:00AM
Aug 2, 2023 07:00AM Editas Medicine Announces Second Quarter 2023 Results and Business Updates
May 16, 2023 04:30PM
May 5, 2023 07:00AM
Apr 27, 2023 09:00AM
Apr 27, 2023 09:00AM
Apr 27, 2023 09:00AM
Nov 17, 2022 07:17AM
Nov 17, 2022 07:15AM Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
Nov 17, 2022 07:15AM
Aug 3, 2022 06:29AM
Aug 3, 2022 06:29AM
Jul 27, 2022 06:31AM
Jul 27, 2022 06:30AM
Jul 27, 2022 06:30AM
May 12, 2022 04:30PM Editas Medicine (EDIT) Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
May 12, 2022 04:30PM
May 12, 2022 04:30PM
May 4, 2022 06:45AM
May 4, 2022 06:45AM
Apr 26, 2022 09:01AM
Apr 26, 2022 09:00AM
Apr 26, 2022 09:00AM Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia
Apr 11, 2022 09:00AM
Apr 11, 2022 09:00AM
Feb 24, 2022 06:30AM
Feb 24, 2022 06:30AM
Feb 8, 2022 09:19AM
Jan 10, 2022 07:00AM
Jan 10, 2022 07:00AM Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
Dec 20, 2021 07:00AM
Dec 20, 2021 07:00AM
Dec 20, 2021 07:00AM
Sep 13, 2021 08:00AM
Sep 7, 2021 06:19AM
Feb 26, 2021 06:53AM
Feb 25, 2021 07:00AM Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
Feb 25, 2021 07:00AM
Feb 8, 2021 08:01AM
Feb 8, 2021 08:00AM
Feb 8, 2021 08:00AM
Jan 20, 2021 09:20AM
Jan 19, 2021 05:44PM
Jan 11, 2021 06:05AM Editas Medicine (EDIT) Reports FDA has Cleared Initiation of EDIT-301 Clinical Trial
Jan 11, 2021 06:02AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All